share_log

JonesTrading Initiates Coverage On Prime Medicine With Buy Rating, Announces Price Target of $20

JonesTrading Initiates Coverage On Prime Medicine With Buy Rating, Announces Price Target of $20

JoneStrading以买入评级开始对Prime Medicine进行保险,宣布目标股价为20美元
Benzinga ·  2023/09/06 04:52

JonesTrading analyst Justin Walsh initiates coverage on Prime Medicine (NASDAQ:PRME) with a Buy rating and announces Price Target of $20.

JoneStrading分析师贾斯汀·沃尔什以买入评级开始对Prime Medicine(纳斯达克股票代码:PRME)进行报道,并宣布目标股价为20美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发